Copyright
©2008 The WJG Press and Baishideng.
World J Gastroenterol. Apr 28, 2008; 14(16): 2494-2500
Published online Apr 28, 2008. doi: 10.3748/wjg.14.2494
Published online Apr 28, 2008. doi: 10.3748/wjg.14.2494
Figure 4 The effect of DHDMBF30 against different mRNA.
A: Against 5-LOX mRNA and COX-2-mRNA in Capan2 cells. Lane 1: COX-2 after inhibition; Lane 2: 5-LOX after inhibition; Lane 3: 5-LOX before inhibition; Lane 4: COX-2 before inhibition; Lane 5: β-actin; Lane 6: Marker; B: Against VEGF mRNA in Capan2 cells. Lane 1: Control group; Lane 2: Treatment group; Lane 3: β-actin; Lane 4: Marker; C: Against the VEGF mRNA of transplant pancreatic tumor cell in the hairless mice. Lane 1: Treatment group; Lane 2: Control group; Lane 3: β-actin; Lane 4: Marker.
- Citation: Zhang B, Wang CL, Zhao WH, Lv M, Wang CY, Zhong WX, Zhou WY, Yu WS, Zhang Y, Li S. Effect of 5-LOX/COX-2 common inhibitor DHDMBF30 on pancreatic cancer cell Capan2. World J Gastroenterol 2008; 14(16): 2494-2500
- URL: https://www.wjgnet.com/1007-9327/full/v14/i16/2494.htm
- DOI: https://dx.doi.org/10.3748/wjg.14.2494